TrialInternational clinical psychopharmacology2020

OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females.

Mitchell F Brin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.